Anti-CD19 Humanized Monoclonal Antibody Conjugated To DM4
Anti-CD19 Humanized Monoclonal Antibody Conjugated To DM4 Uses, Dosage, Side Effects, Food Interaction and all others data.
Anti-CD19 Humanized Monoclonal Antibody Conjugated To DM4 (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).
Table Of contents
| Trade Name | Anti-CD19 Humanized Monoclonal Antibody Conjugated To DM4 |
| Generic | Coltuximab ravtansine |
| Coltuximab ravtansine Other Names | Anti-CD19 humanized monoclonal antibody conjugated to DM4, Coltuximab ravtansine |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in lymphoma (non-hodgkin's).
How Anti-CD19 Humanized Monoclonal Antibody Conjugated To DM4 works
SAR3419 is an anti-CD19-DM4 immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. SAR3419 targets the cell surface antigen CD19, found on a number of B-cell-derived cancers. Upon antibody/antigen binding and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CD19-expressing tumor cells. [National Cancer Institute Drug Dictionary]
Innovators Monograph
You find simplified version here Anti-CD19 Humanized Monoclonal Antibody Conjugated To DM4
